Harmony Biosciences Holdings, Inc. (HRMY) NASDAQ

29.60

+3.33(+12.68%)

Updated at October 23 04:00PM

Currency In USD

Harmony Biosciences Holdings, Inc.

Address

630 West Germantown Pike

Plymouth Meeting, PA 19462

United States of America

Phone

484 539 9800

Sector

Healthcare

Industry

Biotechnology

Employees

268

First IPO Date

August 19, 2020

Key Executives

NameTitlePayYear Born
Dr. Jeffrey M. Dayno M.D.President, Chief Executive Officer & Director1.67M1957
Mr. Jeffrey S. AroninFounder & Non-Executive Chairman40,0001968
Dr. Kumar Budur M.D., M.S.Executive Vice President and Chief Medical & Scientific Officer773,8011971
Mr. Andrew Serafin J.D., M.B.A.Executive Vice President & Chief Strategy Officer791,4041975
Mr. Sandip S. Kapadia CPA, M.B.A.Executive Vice President, Chief Administrative Officer & Chief Financial Officer1.06M1970
Ms. Cate McCanlessSenior Vice President & Chief Corporate Affairs Officer0N/A
Brennan DoyleVice President & Head of Investor Relations0N/A
Mr. Christian Ulrich J.D.General Counsel & Corporate Secretary0N/A
Ms. Audrey Murphy SPHRChief Human Resources Officer0N/A
Ms. Tricia GloverChief Compliance Officer0N/A

Description

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.